Vivesto AB AI Stock Analysis
Want to see SE:VIVE full AI Analyst Report?
Vivesto AB (VIVE) AI Stock Analysis
Vivesto AB
(Nasdaq OMX AB:VIVE)
The score is held down primarily by weak financial performance: Vivesto generates no revenue, posts continued losses (-SEK 31.5 million TTM) and negative free cash flow, leaving it reliant on capital markets and pipeline success. The main offset is a clean, debt-free balance sheet with SEK 158 million of equity funding 94% of assets and a sharply reduced burn rate, which provides a reasonable runway. Technicals add further pressure, with the share trading below all major moving averages and a negative MACD, although extremely oversold RSI and Stochastic readings leave room for a short-term rebound. Valuation offers no support given negative earnings and no dividend. Earnings call and corporate event data were unavailable and excluded, with their weight redistributed across the remaining components.
Vivesto AB (VIVE) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 79.05M
- Dividend Yield
- ―
- Average Volume (3M)
- 7,683
- Price to Earnings (P/E)
- -5.3
- Beta (1Y)
- 0.56
- Revenue Growth
- ―
- EPS Growth
- 37.35%
- Country
- Sweden
- Employees
- 4
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Vivesto AB Business Overview & Revenue Model
Company Description
Vivesto AB, established in 1988 and headquartered in Solna, Sweden, specializes in the development, production, commercialization, and sale of pharmaceutical products within human and veterinary oncology, primarily operating in its home country. Its...
How the Company Makes Money
Vivesto AB’s revenue model is primarily that of a development-stage biopharmaceutical company: it seeks to create shareholder value and future earnings by advancing oncology drug candidates through preclinical and clinical development toward regulato...
Vivesto AB Financial Statement Overview
Summary
Vivesto is a pre-commercial, clinical-stage pharma with essentially no revenue since 2022, resulting in a very weak income statement (score 19) with a TTM operating loss of SEK 31.5 million and slightly negative gross profit. Cash flow remains negative (score 32), though operating outflow has narrowed sharply from -SEK 146 million in 2021 to -SEK 29.6 million TTM. The balance sheet is the key offset (score 61): the company is debt-free, equity of SEK 158.3 million funds about 94% of total assets, and capital was recently replenished, implying a multi-year runway at the current burn. Offsetting this, equity has eroded from SEK 550 million in 2021, return on equity is about -22%, and the company remains dependent on external funding and pipeline execution.
Income Statement
19Very NegativeBalance Sheet
61PositiveCash Flow
32Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 0 | 0 | 1.01M | 26.19M |
| Gross Profit | -478.00K | 0 | -3.19M | 0 | -10.66M | -17.93M |
| EBITDA | -31.00M | -34.38M | -36.56M | -123.79M | -100.56M | -99.77M |
| Net Income | -31.54M | -34.08M | -39.75M | -128.74M | -367.03M | -138.94M |
Balance Sheet | ||||||
| Total Assets | 168.56M | 149.04M | 172.88M | 220.67M | 355.88M | 594.31M |
| Cash, Cash Equivalents and Short-Term Investments | 23.51M | 2.10M | 32.29M | 77.04M | 142.51M | 97.27M |
| Total Debt | 0 | 13.00M | 0 | 0 | 8.17M | 10.43M |
| Total Liabilities | 10.30M | 24.46M | 14.55M | 22.87M | 30.45M | 44.59M |
| Stockholders Equity | 158.26M | 124.58M | 158.33M | 197.80M | 325.42M | 549.71M |
Cash Flow | ||||||
| Free Cash Flow | -24.64M | -43.81M | -47.25M | -69.40M | -80.79M | -179.91M |
| Operating Cash Flow | -29.64M | -33.96M | -47.25M | -68.74M | -80.52M | -145.56M |
| Investing Cash Flow | -18.55M | 21.85M | 43.40M | 63.73M | -45.28M | 118.65M |
| Financing Cash Flow | 48.94M | 13.00M | 0 | 0 | 128.76M | -5.81M |
Vivesto AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:VIVE, the sentiment is Negative. The current price of 7.14 is below the 20-day moving average (MA) of 7.34, below the 50-day MA of 7.86, and below the 200-day MA of 8.53, indicating a bearish trend. The MACD of -0.15 indicates Negative momentum. The RSI at 43.47 is Neutral, neither overbought nor oversold. The STOCH value of 26.29 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:VIVE.
Vivesto AB Peers Comparison
Overall Rating
SE:NANEXA67Neutral
SE:NICA46Neutral
SE:SPAGO42Neutral
SE:VIVE41Neutral
SE:SPEC40Underperform
SE:CLS.B38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 67Neutral | SEK 1.90B | 12.98 | 87.15% | ― | 2370.13% | ― | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | SEK 57.37M | 0.50 | 23.67% | ― | 163.58% | ― | |
| 42Neutral | SEK 35.13M | -1.05 | -87.37% | ― | -97.52% | 31.31% | |
| 41Neutral | SEK 79.05M | -5.32 | -20.29% | ― | ― | 37.35% | |
| 40Underperform | SEK 19.12M | -0.31 | -25.90% | ― | ― | 78.15% | |
| 38Underperform | SEK 78.99M | -1.17 | -66.41% | ― | -47.42% | 44.01% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:VIVE | Vivesto AB | 7.14 | -7.10 | -49.86% | |
| SE:CLS.B | Clinical Laserthermia Systems AB Class B | 1.58 | -5.16 | -76.53% | |
| SE:SPEC | SpectraCure AB | 0.01 | -0.11 | -90.08% | |
| SE:NICA | Nanologica AB | 0.17 | -0.83 | -82.70% | |
| SE:SPAGO | Spago Nanomedical AB | 0.04 | -0.06 | -59.00% | |
| SE:NANEXA | Nanexa AB | 9.92 | 8.23 | 486.98% |
Vivesto AB Corporate Events
Vivesto’s Paccal Vet Data Spotlighted at Key Veterinary Oncology Conference
Vivesto AB announced that topline data from its Paccal Vet clinical studies in dogs and cats are being presented in two posters at the Veterinary Cancer Society Annual Conference 2026 in Minneapolis, reinforcing the company’s growing presence in vete...
Vivesto’s Paccal Vet Shows Promising Efficacy and Safety in Feline Cancer Study
Vivesto AB has reported positive topline results from its dose-finding study of Paccal Vet in cats with solid tumors, showing clear indications of anti-tumor activity across multiple tumor types. The trial enrolled 21 cats and identified biological r...
Vivesto’s Paccal Vet Shows Survival Benefit in Canine Hemangiosarcoma Study
Vivesto AB has reported positive topline results from an open-label pilot study of its veterinary cancer drug candidate Paccal Vet in dogs with Stage I-II splenic hemangiosarcoma following splenectomy. The median overall survival of 135 days exceeded...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 08, 2026
